AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

AML.AU AEON METALS LTD

Not Yet Opened 05-17 16:12:00 AEST

0.01

+0.00

0.00%

High0.01	Low0.01	Vol241.70K
Open0.01	D1 Closing0.01	Amplitude0.00%
Mkt Cap6.58M	Tradable Cap2.60M	Total Shares1.10B
T/O1.45K	T/O Rate0.06%	Tradable Shares433.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"AML.AU","market":"AU","secType":"STK","nameCN":"AEON METALS LTD","latestPrice":0.006,"timestamp":1715926320000,"preClose":0.006,"halted":0,"volume":241703,"delay":0,"nameEN":"AEON METALS LTD","floatShares":433235140,"shares":1096400622,"eps":-0.007335,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-17 16:12:00 AEST","open":0.006,"high":0.006,"low":0.006,"amount":1450,"amplitude":0,"askPrice":0.007,"askSize":300000,"bidPrice":0.006,"bidSize":3242937,"shortable":3,"etf":0,"ttmEps":-0.007335,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1716163200000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.006,"openAndCloseTimeList":[[1715904000000,1715925600000]],"volumeRatio":0.6207294881236666,"lotSize":1,"tradeCurrency":"AUD"},"requestUrl":"/m/hq/s/AML.AU","defaultTab":"news","newsList":[{"id":"2435329587","title":"Press Release: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2435329587","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435329587?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:30","pubTimestamp":1715599800,"startTime":"0","endTime":"0","summary":"--     Recently announced interim data from ongoing MB-106 study demonstrating Annamycin in combination with Cytarabine  achieves CRc rate of 62%  in 1 and 2 line AML subjects . --     Also announced MB-106 reaches 20 subjects enrolled. --     Company to host conference call and webcast today, Monday, May 13 at 8:30 AM ET. \"We recently hosted a virtual AML Clinical Day featuring renowned KOLs, Dr. Martin Tallman and Dr. Michael Andreeff. It was great to hear their support of and thoughts on Annamycin's recent developments in AML. You can hear that discussion here. Combined with the encouraging Annamycin data demonstrated to date and the positive feedback from the KOLs, we continue to believe that our results in 2 line subjects fill a significant unmet need. We believe this is supported by the exceptional  CRc rate demonstrated by AnnAraC in 2 line patients, which substantially exceeds the performance reported by any drug currently approved in the U.S. for use in 2 line AML. We believe ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2434138092","title":"Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals","url":"https://stock-news.laohu8.com/highlight/detail?id=2434138092","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2434138092?lang=en_us&edition=fundamental","pubTime":"2024-05-12 15:45","pubTimestamp":1715499900,"startTime":"0","endTime":"0","summary":"Hangzhou Sciwind Biosciences out-licenses South Korean rights for ecnoglutide injection to HK inno.N Corporation for up to $56 million.Beijing's Sino Biological completes its $48 million acquisition o","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/650506912/image_650506912.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/650506912/image_650506912.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4692506-week-in-review-sciwind-sino-biological-and-biocytogen-announce-deals","is_publish_highlight":false,"gpt_icon":0},{"id":"2434500047","title":"Press Release: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2434500047","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2434500047?lang=en_us&edition=fundamental","pubTime":"2024-05-10 04:01","pubTimestamp":1715284860,"startTime":"0","endTime":"0","summary":"Dose escalation of zotatifin in the ZFA triplet ongoing at 0.14 mg/kg, with RP2D expected in H2 2024. Raised $15.0 million in gross proceeds from registered direct financing, extending cash runway into first quarter of 2025. SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 09, 2024  -- eFFECTOR Therapeutics, Inc. , a leader in the development of selective translation regulator inhibitors  for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.\"We had a productive first quarter marked by continued progress in the zotatifin program, including successful completion of the ZF doublet dose escalation, and ongoing assessment of increasing doses in the ZFA triplet,\" said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. \"We are highly encouraged with the safety profile and activity already reported for the ZFA triplet, in particular the 7.4 month mPFS in heavily pre-treated patients, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433661401","title":"Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2433661401","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433661401?lang=en_us&edition=fundamental","pubTime":"2024-05-07 00:03","pubTimestamp":1715011380,"startTime":"0","endTime":"0","summary":"-- Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial. -- Company planning to request an End-of-Phase II meeting with the FDA to. discuss plans for a registrational Phase III trial in BPD. grant in the EU and Korea for patent application covering the use of. Dr Carlos Buesa, Oryzon's Chief Executive Officer, said: \"Oryzon continued with a strong path in its clinical programs in the first quarter. In CNS, following presentation in January of topline data from our Phase IIb PORTICO trial evaluating vafidemstat as a treatment for Borderline Personality Disorder , we are finalizing the full data set analysis. The company is preparing the request of an End-of-Phase II meeting with the FDA to discuss the design of a Phase III. Our Phase IIb trial with vafidemstat in schizophrenia, EVOLUTION, has also continued to enroll patients. Importantly, we have received from the European Patent Office  an \"intention to grant\" communication for Oryzon's European patent application ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2433447541","title":"Press Release: GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433447541","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2433447541?lang=en_us&edition=fundamental","pubTime":"2024-05-06 18:00","pubTimestamp":1714989600,"startTime":"0","endTime":"0","summary":"--  Study of uproleselan combined with chemotherapy did not meet its. primary endpoint of overall survival in the intent to treat population. --  Adverse events were consistent with known side effect profiles of. --  Comprehensive data analysis with medical, statistical, and regulatory. experts underway and will be shared as appropriate; company will submit. results for presentation at an upcoming medical meeting. --  National Cancer Institute  Phase 2/3 study in newly diagnosed AML. GlycoMimetics, Inc. , a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone.The NCI and the Alliance for Clinical Trials i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2430745706","title":"Nkarta: Down 50% Since March With A Clinical Catalyst Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2430745706","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430745706?lang=en_us&edition=fundamental","pubTime":"2024-04-27 22:27","pubTimestamp":1714228020,"startTime":"0","endTime":"0","summary":"NKTX is now down over 50% from its March 2024 highs.The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease.NKTX has already produced some data wi","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412352157/image_1412352157.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1412352157/image_1412352157.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687011-nkarta-down-50-percent-since-march-with-a-clinical-catalyst-ahead","is_publish_highlight":false,"gpt_icon":0},{"id":"2428510511","title":"Jazz Pharmaceuticals: Cheap But Complicated","url":"https://stock-news.laohu8.com/highlight/detail?id=2428510511","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428510511?lang=en_us&edition=fundamental","pubTime":"2024-04-19 01:26","pubTimestamp":1713461198,"startTime":"0","endTime":"0","summary":"Jazz Pharmaceuticals plc has a neuroscience franchise that is led by Xywav, which has replaced Xyrem as the top treatment for narcolepsy.The company's narcolepsy franchise is facing competition from A","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149615583/image_149615583.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/149615583/image_149615583.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4684510-jazz-pharmaceuticals-cheap-but-complicated","is_publish_highlight":false,"gpt_icon":0},{"id":"2428073593","title":"HOLO, SNTG and LRHC are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2428073593","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428073593?lang=en_us&edition=fundamental","pubTime":"2024-04-18 20:40","pubTimestamp":1713444055,"startTime":"0","endTime":"0","summary":"Gainers: Bio-Path Holdings (BPTH) +61% Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4090954-holo-sntg-and-lrhc-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2425587649","title":"4 Pharma & Biotech Stocks on the Move in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2425587649","media":"LiveWire","top":-1,"share":"https://ttm.financial/m/news/2425587649?lang=en_us&edition=fundamental","pubTime":"2024-04-08 15:25","pubTimestamp":1712561140,"startTime":"0","endTime":"0","summary":"The Pharma and Biotech market was relatively buoyant in March      with 49% of share prices in the coverage universe increasing for the month. There was some significant news flow which resulted in a strong uplift in share prices for some companies. Below we take a look at four companies whose share prices rallied strongly during the month.During the month, Osteopore also provided an interim update on the single-arm feasibility clinical trials being conducted in Australia for cranial and long bone reconstruction using polycaprolactone-tricalcium phosphate customised scaffolds. Each study aimed to recruit 5-10 patients, however the long bone construction trial has now been closed with the recruitment of only 2 patients with patient recruitment proving difficult. The cranial reconstruction trial is now complete with 9 patients participating. 3 patients have reached the post-surgery milestone of 24 months, 1 is at 18 months and 5 are between 1 and 9 months. The study has shown that the cu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"livewire_stock","url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-march","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.livewiremarkets.com/wires/4-pharma-biotech-stocks-on-the-move-in-march","is_publish_highlight":false,"gpt_icon":0},{"id":"2422816604","title":"Press Release: CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2422816604","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2422816604?lang=en_us&edition=fundamental","pubTime":"2024-03-28 19:00","pubTimestamp":1711623600,"startTime":"0","endTime":"0","summary":"BEIJING, March 28, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. , a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.CASI reported fourth quarter 2023 revenue of $6.9 million for EVOMELA , 33% lower than the same period in 2022. The 2023 full-year revenue of $34 million reflects an 11% of decrease compared to 2022. Wei-Wu He, Ph.D., CASI's Chairman and Chief Executive Officer, said \"CASI's team has navigated our business through a challenging external environment. We have successfully brought the second commercial product FOLOTYN to China market as a treatment for patients with relapsed or refractory peripheral T-cell lymphoma . We will continue to strengthen the commercial franchise throughout 2024 and beyond. At the same time, our regulatory and development t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2422913766","title":"Press Release: Ascentage Pharma Announces 2023 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2422913766","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2422913766?lang=en_us&edition=fundamental","pubTime":"2024-03-27 22:30","pubTimestamp":1711549800,"startTime":"0","endTime":"0","summary":"SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma , a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B , and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved rapid progress with its patient-centric global innovation strategy, and delivered numerous milestones in clinical development and global expansion.Newly approved indication of olverembatinib expands the drug's addressable market. In 2023, Ascentage Pharma recorded a revenue of RMB222 million, most of which was attributable to product sales and milestone payments, including a revenue of RMB194 million from product sales. For the first time, the company achieved commercial breakeven through topline growth while keeping selling and distribution expenses at a manageable level and signif","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aeonmetals.com.au","stockEarnings":[{"period":"1week","weight":-0.1429},{"period":"1month","weight":0.2},{"period":"3month","weight":-0.1429},{"period":"6month","weight":-0.3333},{"period":"1year","weight":-0.6667},{"period":"ytd","weight":-0.4545}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0587},{"period":"3month","weight":0.0966},{"period":"6month","weight":0.1366},{"period":"1year","weight":0.1436},{"period":"ytd","weight":0.1212}],"compareStock":{"symbol":"F100.AU","name":"BETASHARES FTSE 100 ETF"},"description":"Aeon Metals Limited explores for and develops mineral properties in Australia. The company primarily explores for copper, cobalt, gold, lead, zinc, molybdenum, silver, and base metal deposits. Its flagship property is the Walford Creek project comprising 4 exploration permits covering an area of 211.6 square kilometers located in northwest Queensland. The company was formerly known as Aussie Q Resources Limited and changed its name to Aeon Metals Limited in August 2012. Aeon Metals Limited was incorporated in 2006 and is headquartered in Sydney, Australia.","yearOnYearQuotes":[{"month":1,"riseRate":0.470588,"avgChangeRate":0.068448},{"month":2,"riseRate":0.411765,"avgChangeRate":-0.014054},{"month":3,"riseRate":0.294118,"avgChangeRate":-0.051354},{"month":4,"riseRate":0.470588,"avgChangeRate":0.097714},{"month":5,"riseRate":0.125,"avgChangeRate":-0.127824},{"month":6,"riseRate":0.588235,"avgChangeRate":0.21765},{"month":7,"riseRate":0.352941,"avgChangeRate":-0.046612},{"month":8,"riseRate":0.588235,"avgChangeRate":0.027533},{"month":9,"riseRate":0.235294,"avgChangeRate":-0.101363},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.024502},{"month":11,"riseRate":0.352941,"avgChangeRate":-0.009087},{"month":12,"riseRate":0.411765,"avgChangeRate":0.201763}],"exchange":"ASX","name":"AEON METALS LTD","nameEN":"AEON METALS LTD"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AEON METALS LTD(AML.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AEON METALS LTD,AML.AU,AEON METALS LTD股票,AEON METALS LTD股票老虎,AEON METALS LTD股票老虎国际,AEON METALS LTD行情,AEON METALS LTD股票行情,AEON METALS LTD股价,AEON METALS LTD股市,AEON METALS LTD股票价格,AEON METALS LTD股票交易,AEON METALS LTD股票购买,AEON METALS LTD股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AEON METALS LTD(AML.AU),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AEON METALS LTD(AML.AU) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction